Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) prior to treatment with crizanlizumab | Up to 12 months | |
| Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) during treatment with crizanlizumab | Up to 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients who discontinued treatment with crizanlizumab | Up to 24 months | |
| Number of doses of crizanlizumab for patients who discontinued treatment with crizanlizumab | Up to 24 months | |
Not provided
Inclusion criteria:
Exclusion criteria:
None specified
Not provided
Not provided
Not provided
Not provided
This was a retrospective, noninterventional cohort study
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Alabama Birmingham | Birmingham | Alabama | 35233 | United States | ||
| Cristiana Care |
Not provided
Not provided
Not provided
Not provided
| Reasons for early discontinuation of crizanlizumab treatment |
| Up to 24 months |
| Number of sickle cell disease (SCD)-related hospitalizations | Up to 24 months |
| Number of SCD-related emergency department (ED) visits | Up to 24 months |
| Wilmington |
| Delaware |
| 19801 |
| United States |
| All Children's Hospital | St. Petersburg | Florida | 33701 | United States |
| Johns Hopkins University | Baltimore | Maryland | 21205 | United States |
| Washington University of St. Louis | St Louis | Missouri | 63110 | United States |
| Beth Israel Hospital | East Hanover | New Jersey | 07936 | United States |
| Montefiore | New York | New York | 10461 | United States |
| University of North Carolina | Chapel Hill | North Carolina | 27514 | United States |
| University Hospital at Cleveland Medical Center | Cleveland | Ohio | 44106 | United States |
| Ohio State University | Columbus | Ohio | 43203 | United States |
| University of Texas (Houston) | Houston | Texas | 77030 | United States |
| ID | Term |
|---|---|
| D000755 | Anemia, Sickle Cell |
| ID | Term |
|---|---|
| D000745 | Anemia, Hemolytic, Congenital |
| D000743 | Anemia, Hemolytic |
| D000740 | Anemia |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D006453 | Hemoglobinopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided